New hospital disinfection processes for both conventional and prion infectious agents compatible with thermosensitive medical equipment

Autor: Lehmann, S., Pastore, M., Rogez-Kreuz, C., Richard, M., Belondrade, M., Rauwel, G., Durand, F., Yousfi, R., Criquelion, J., Clayette, P., Perret-Liaudet, A.

Publikováno v: In Journal of Hospital Infection 2009 72(4):342-350

Advancing surgical instrument safety: A screen of oxidative and alkaline prion decontaminants using real-time quaking-induced conversion with prion-coated steel beads as surgical instrument mimetic.

Autor: Heinzer, Daniel¹ (AUTHOR), Avar, Merve¹ (AUTHOR), Pfammatter, Manuela¹ (AUTHOR), Moos, Rita¹ (AUTHOR), Schwarz, Petra¹ (AUTHOR), Buhmann, Matthias T.² (AUTHOR), Kuhn, Benjamin² (AUTHOR), Mauerhofer, Stefan² (AUTHOR), Rosenberg, Urs² (AUTHOR), Aguzzi, Adriano¹ (AUTHOR), Hornemann, Simone¹ (AUTHOR) simone.hornemann@usz.ch

Publikováno v: PLoS ONE. 6/13/2024, Vol. 19 Issue 6, p1-20. 20p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Identification of Vaccine-Altered Circulating B Cell Phenotypes Using Mass Cytometry and a Two-Step Clustering Analysis.

Autor: Pejoski D; University of Paris South, U1184, 92265 Fontenay-aux-Roses, France; French Atomic Energy and Alternative Energies Commission, Organization for the Direction of Fundamental Research/Institute of Emerging Diseases and Innovative Therapies, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, 92265 Fontenay-aux-Roses, France; INSERM, U1184, 94276 Le Kremlin-Bicêtre, France; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France;, Tchitchek N; University of Paris South, U1184, 92265 Fontenay-aux-Roses, France; French Atomic Energy and Alternative Energies Commission, Organization for the Direction of Fundamental Research/Institute of Emerging Diseases and Innovative Therapies, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, 92265 Fontenay-aux-Roses, France; INSERM, U1184, 94276 Le Kremlin-Bicêtre, France; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France;, Rodriguez Pozo A; University of Paris South, U1184, 92265 Fontenay-aux-Roses, France; French Atomic Energy and Alternative Energies Commission, Organization for the Direction of Fundamental Research/Institute of Emerging Diseases and Innovative Therapies, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, 92265 Fontenay-aux-Roses, France; INSERM, U1184, 94276 Le Kremlin-Bicêtre, France; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France;, Elhmouzi-Younes J; University of Paris South, U1184, 92265 Fontenay-aux-Roses, France; French Atomic Energy and Alternative Energies Commission, Organization for the Direction of Fundamental Research/Institute of Emerging Diseases and Innovative Therapies, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, 92265 Fontenay-aux-Roses, France; INSERM, U1184, 94276 Le Kremlin-Bicêtre, France; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France;, Yousfi-Bogniaho R; ImmunoPharmacology and Biosafety Laboratory, BERTIN Pharma, French Atomic Energy and Alternative Energies Commission, 92265 Fontenay-aux-Roses, France; and., Rogez-Kreuz C; ImmunoPharmacology and Biosafety Laboratory, BERTIN Pharma, French Atomic Energy and Alternative Energies Commission, 92265 Fontenay-aux-Roses, France; and., Clayette P; ImmunoPharmacology and Biosafety Laboratory, BERTIN Pharma, French Atomic Energy and Alternative Energies Commission, 92265 Fontenay-aux-Roses, France; and., Dereuddre-Bosquet N; University of Paris South, U1184, 92265 Fontenay-aux-Roses, France; French Atomic Energy and Alternative Energies Commission, Organization for the Direction of Fundamental Research/Institute of Emerging Diseases and Innovative Therapies, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, 92265 Fontenay-aux-Roses, France; INSERM, U1184, 94276 Le Kremlin-Bicêtre, France; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France;, Lévy Y; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France; INSERM, U955, Team 16, Clinical and Infectious Diseases Department, Hospital Henri Mondor, University of Paris East, 94010 Créteil, France., Cosma A; University of Paris South, U1184, 92265 Fontenay-aux-Roses, France; French Atomic Energy and Alternative Energies Commission, Organization for the Direction of Fundamental Research/Institute of Emerging Diseases and Innovative Therapies, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, 92265 Fontenay-aux-Roses, France; INSERM, U1184, 94276 Le Kremlin-Bicêtre, France; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France;, Le Grand R; University of Paris South, U1184, 92265 Fontenay-aux-Roses, France; French Atomic Energy and Alternative Energies Commission, Organization for the Direction of Fundamental Research/Institute of Emerging Diseases and Innovative Therapies, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, 92265 Fontenay-aux-Roses, France; INSERM, U1184, 94276 Le Kremlin-Bicêtre, France; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France;, Beignon AS; University of Paris South, U1184, 92265 Fontenay-aux-Roses, France; French Atomic Energy and Alternative Energies Commission, Organization for the Direction of Fundamental Research/Institute of Emerging Diseases and Innovative Therapies, U1184, Immunology of Viral Infections and Autoimmune Diseases, Infectious Disease Models and Innovative Therapies Infrastructure, 92265 Fontenay-aux-Roses, France; INSERM, U1184, 94276 Le Kremlin-Bicêtre, France; Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France; anne-sophie.beignon@cea.fr.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2016 Jun 01; Vol. 196 (11), pp. 4814-31. Date of Electronic Publication: 2016 May 02.